What must a new drug prove to beat propofol?
The first hurdle is efficacy: the new drug must reliably induce general anesthesia without needing rescue sedation. In a 2021 randomized trial, remimazolam at 0.4 mg/kg achieved a 100% success rate, exactly matching propofol, while lower doses (0.2 and 0.3 mg/kg) were less reliable (89% and 94%) [1]. This means that to be a viable alternative, a new drug must hit a dose that works as consistently as the standard agent—otherwise it's not a real option.
The second hurdle is safety: the new drug must reduce the risk of serious adverse events that propofol is known for. In the same trial, propofol caused hypotension (low blood pressure) in 44% of patients, while remimazolam at 0.2 and 0.3 mg/kg caused it in only 13% and 24% [1]. Even at the highest remimazolam dose, hypotension was 34%, still lower than propofol [1]. This is a concrete, patient-relevant advantage: fewer dangerous drops in blood pressure during induction.
What side-effect advantages matter most?
Injection pain is a common complaint with propofol, and a new drug can win points by eliminating it. In the 2021 trial, 27% of patients given propofol reported injection pain, while no patients in any remimazolam group did [1]. That's a clear, immediate patient comfort win.
Another major advantage is reversibility. Remimazolam is a benzodiazepine, so its effects can be reversed with flumazenil, a specific antidote [4]. This is a safety net that propofol doesn't have—if something goes wrong, you can actively reverse the drug. The 2022 review also notes that remimazolam has a low liability for cardiovascular and respiratory depression compared to propofol, which is a key selling point for high-risk patients [2].
Where do these advantages apply—and where don't they?
The evidence for remimazolam's advantages comes mainly from healthy patients (ASA I or II) undergoing elective surgery, so the benefits may not automatically extend to sicker patients or complex surgeries [1]. The 2022 review on total intravenous anesthesia (TIVA) for liver resections points out that propofol-based TIVA has its own benefits, like antiemetic effects and smoother emergence, which are important in major abdominal surgery [3]. So a new drug must also match or beat propofol on recovery quality and postoperative nausea, not just induction safety.
The setting matters too: remimazolam has been approved for procedural sedation and general anesthesia in various countries, but its role in intensive care or long surgeries is still being explored [4]. The 2022 review emphasizes that while remimazolam's pharmacokinetics (how the body processes it) are predictable, more data are needed in different patient populations and surgical conditions [2]. So a new drug's advantages must be proven in the specific context where it will be used, not just in healthy volunteers.
About These Sources
This answer is built on 4 peer-reviewed studies — published from 2021 to 2022, 4 in Q1 journals, collectively cited 545 times — selected as the most relevant from 4 studies that passed quality screening, drawn from 42 papers retrieved from a database of over 500 million.
Sources used in this answer
Safety and efficacy of remimazolam compared with propofol in induction of general anesthesia
In a randomized trial of 189 healthy (ASA I-II) patients, remimazolam at 0.4 mg/kg achieved 100% successful induction, matching propofol, but caused hypotension in only 34% of patients versus 44% with propofol, and no injection pain versus 27% with propofol.
Remimazolam – current knowledge on a new intravenous benzodiazepine anesthetic agent
A 2022 review of remimazolam's pharmacology concludes it offers predictable sedation and rapid recovery, with lower risks of hemodynamic instability and respiratory depression compared to propofol, but notes that data in diverse patient populations are still limited.
Total intravenous anesthesia for liver resections: anesthetic implications and safety
A 2022 review on TIVA for liver resections highlights propofol-based TIVA's benefits—antiemetic properties, smooth emergence, and potential immune benefits—and discusses barriers to its adoption, suggesting that new agents must match these advantages in complex surgeries.
Remimazolam: Non-Clinical and Clinical Profile of a New Sedative/Anesthetic Agent
A 2021 review of remimazolam's development and profile shows it is a rapid-onset, short-acting benzodiazepine with low cardiovascular and respiratory depression, and that its effects can be reversed with flumazenil, differentiating it from propofol.